)
)
Skye Bioscience Investor Relations Material
Latest events
Q3 2024
Skye Bioscience
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Skye Bioscience Inc
Access all reports
Skye Bioscience, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapeutic solutions targeting the endocannabinoid system (ECS). The company's primary focus is on conditions such as obesity, chronic kidney disease, and glaucoma. Skye's portfolio includes drug candidates like nimacimab, a monoclonal antibody that acts as a CB1 receptor inhibitor, and SBI-100 Ophthalmic Emulsion, designed to reduce intraocular pressure in glaucoma patients. The company is headquartered in San Diego, California, and its shares are listed on the NASDAQ.
Latest articles
)
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
)
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
)
Mips: The Gore-Tex of Brain Protection
How Mips turned a critical safety flaw into a global success, redefining helmet protection with its technology and ingredient brand business model.
24 Jan 2025
Ticker symbol
SKYE
Country
🇺🇸 United States